🔗 Share this article

Elected officials have raised concerns that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on drug pricing, which commits to zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond limited headline terms outlined by government press releases.

An Agreement in Principle Only

The deal on drug tariffs, promoted as a "landmark" achievement, remains an "broad understanding" without detailed provisions. It has been highlighted that the public statements from the UK and US governments describe the deal in divergent terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the agreement for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for little more than a pledge from President Trump," said David Henig, a trade expert. "It is documented he has a tendency for not following through on agreements."

A Pattern of Unreliability

Concerns have been amplified by Washington's recent decision to pause the major technology agreement, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions promised for British farmers as part of an May trade agreement have yet to be formally approved by the US, despite a fast-approaching January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have admitted unease that the government's agreements with the US are unstable and unpredictable. One minister was quoted as stating the series of agreements as "built on sand," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have downplayed the risk of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, problems have emerged in implementing the broader trade deal. Promised reciprocal agricultural allowances have not materialized, and the assurance to "remove tariffs on British steel and aluminium" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.